Harbin Gloria Pharmaceuticals Co., Ltd

002437

CNE100000QG8

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 14/05/2024 BST			5-day change	1st Jan Change
2.15 ^CNY	-0.46%		-1.38%	-14.34%

04-26	HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-12	HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Harbin Gloria Pharmaceuticals Co., Ltd(XSEC:002437) dropped from S&P Global BMI Index

December 20, 2021 at 05:00 am

Latest news about Harbin Gloria Pharmaceuticals Co., Ltd

HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2023	04-12	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD completed the acquisition of additional 10% stake in Harbin Dandelion Pharmaceuticals Co., Ltd. from Harbin Hanjun Investment Co., Ltd.	27/10/23	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2023	26/10/23	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD agreed to acquire additional 10% stake in Harbin Dandelion Pharmaceuticals Co., Ltd. from Harbin Hanjun Investment Co., Ltd. for CNY 35 million.	16/10/23	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD(XSEC:002437) added to S&P Global BMI Index	18/09/23	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2023	28/07/23	CI
Harbin Gloria Pharma Offloads Entire 42% Stake in Biotech Unit for 240 Million Yuan	29/06/23	MT
Harbin Gloria Pharma Offloads Entire 42% Stake in Biotech Unit for 240 Million Yuan	29/06/23	MT
Qingdao Pusheng Puli Enterprise Management Center (Limited Partnership) agreed to acquire 42.1204% stake in Guangzhou Gloria Biosciences Co., Ltd. from HARBIN GLORIA PHARMACEUTICALS Co., LTD for CNY240 million.	28/06/23	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD announced that it expects to receive CNY 300 million in funding	14/05/23	CI
Harbin Gloria Pharmaceuticals Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23/04/23	CI
Consortium of buyers completed the acquisition of a 32.13% stake in Harbin Gloria Pharmaceuticals Co., Ltd from Harbin Gloria Group Co., Ltd.	06/04/23	CI
Harbin Gloria Pharma Swings to Loss in 2022 on Asset Impairment	11/01/23	MT
Harbin Gloria Pharmaceuticals Co., Ltd Announces Executive Appointments	21/12/22	CI
Harbin Gloria Pharmaceuticals Co., Ltd Approves Executive Appointments	14/11/22	CI
Harbin Gloria Pharmaceuticals Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	26/10/22	CI
Harbin Gloria Pharmaceuticals Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	28/08/22	CI
Guangzhou Gloria Biosciences Co., Ltd. announced that it expects to receive CNY 200 million in funding from Harbin Gloria Pharmaceuticals Co., Ltd	12/05/22	CI
Harbin Gloria Pharmaceuticals Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	25/04/22	CI
Harbin Gloria Pharmaceuticals Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	25/04/22	CI
Harbin Gloria Pharmaceuticals Co., Ltd(XSEC:002437) dropped from S&P Global BMI Index	20/12/21	CI
Harbin Gloria Pharmaceuticals Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021	28/10/21	CI
Harbin Gloria Pharmaceuticals Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2021	27/08/21	CI
Harbin Gloria Pharmaceuticals Co., Ltd Announces Earnings Results for the First Quarter Ended March 31, 2021	28/04/21	CI

Chart Harbin Gloria Pharmaceuticals Co., Ltd

Duration

Period

Chart Harbin Gloria Pharmaceuticals Co., Ltd

More charts

HARBIN GLORIA PHARMACEUTICALS Co., LTD is a China-based company, principally engaged in the manufacture and distribution of pharmaceuticals. The Company's products include cardiovascular and cerebrovascular drugs, orthopedic drugs, nutritional drugs, anti-infective drugs, immune-enhancing drugs, diabetes drugs, antineoplastic drugs and electrolytes drugs. The Company is also engaged in the agency, research and development of pharmaceuticals, the provision of clinical services and financial investment business. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

27/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
HARBIN GLORIA PHARMACEUTICALS CO., LTD	-14.34%	678M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.28%	44.4B
OTSUKA HOLDINGS CO., LTD.	+24.60%	23.03B
SANDOZ GROUP AG	+19.22%	15.14B
CIPLA LIMITED	+12.87%	13.12B
ZYDUS LIFESCIENCES LIMITED	+44.67%	11.85B
ONO PHARMACEUTICAL CO., LTD.	-8.33%	6.99B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+12.22%	5.52B